Arena Pharmaceuticals

Clinical-stage biotech focused on cardiovascular, central nervous system, inflammatory and metabolic diseases. Their leading drug candidate is lorcaserin hydrochloride, which recently received positive data from a clinical trial. They are headquartered in San Diego, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) to Pfizer Inc. for $100.00 per share in cash is fair to Arena shareholders. Halper Sadeh encourages Arena shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Arena a

Arena Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Arena Pharmaceuticals, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – ARNA

Pfizer

Arena's stock surge comes after the price this year had dropped by 35%.

Arena Pharmaceuticals soars 97% as Pfizer to spend $6.7 billion to buy ulcerative colitis drug developer

Analysts are on board with Pfizer Inc.'s PFE, +1.34% plans to acquire Arena Pharmaceuticals Inc. ARNA, -5.33% in a deal worth $6.7 billion and announced Monday morning. Pfizer's stock was up 1.2% in premarket trading on Monday, while shares of Arena soared 88.3%.

Analysts: Pfizer to 'capitalize' on experimental colitis treatment in Arena deal

The stock price of Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) increased by over 85% pre-market today. This is why it happened.

Arena Pharmaceuticals Stock (ARNA): Why The Price Surged Today

Pfizer Inc (NYSE: PFE) has agreed to acquire Arena Pharmaceuticals Inc (NASDAQ: ARNA), a clinical-stage company developing therapies to treat several immuno-inflammatory diseases.  Under the agreement terms, Pfizer will acquire Arena for $100 per share in an all-cash transaction for a total equity value of approximately $6.7 billion.

After Blood Cancer, Pfizer Now Bolsters Its Inflammatory Diseases Pipeline With $6.7B Arena Deal

Pfizer agrees to buy U.S. biotech company Arena Pharmaceuticals in a deal valued at about $6.7 billion, according to a regulator filing Monday.

Pfizer to Buy Arena Pharmaceuticals in $6.7 Billion Deal

NEW YORK & PARK CITY, Utah--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Arena, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases. Under the terms of the agreement, Pfizer will acquire all the outstanding shares of Arena for $100 per share in an all-cash transaction for a

Pfizer to Acquire Arena Pharmaceuticals

(Reuters) -Pfizer Inc has agreed to acquire Arena Pharmaceuticals in a $6.7 billion all-cash deal to expand its cancer and inflammatory disease treatment pipeline, the companies said on Monday.

Pfizer to buy Arena Pharmaceuticals for $6.7 billion

Pfizer Inc. PFE, +1.34% said Monday it has agreed to acquire Arena Pharmaceuticals Inc. ARNA, -5.33% in a deal with a value of about $6.7 billion. The news sent Arena shares up 91% in premarket trading.

Pfizer to acquire Arena Pharmaceuticals in deal valued at about $6.7 billion

Aurora Cannabis

AFC Gamma

Agrify

Alpine Global Premier Properties Fund

Cambria Global Real Estate ETF

Canopy Growth

Clever Leaves Holdings Inc

Amplify Seymour Cannabis ETF

Cardiol Therapeutics

Cronos Group

Direxion Daily CSI China Internet Index Bull 2X Shares

WisdomTree Global ex-US Real Estate Fund

Invesco S&P 500 Equal Weight Real Estate ETF

First Trust FTSE EPRA/NAREIT Developed Markets Real Estate

Fidelity MSCI Real Estate ETF

First Trust S&P REIT Index Fund

Greenlane Holdings

FlexShares Global Quality Real Estate Index Fund

GrowGeneration Corp

Xtrackers International Real Estate ETF

High Tide

Hydrofarm Holdings Group

High on Growth: Cannabis REITs are far-and-away the best-performing REIT sector of the past half-decade as the budding industry thrives in the murky and often contradictory regulatory framework of legalized marijuana. Joining Innovative Industrial, Power REIT, and AFC Gamma, a pair of newcomers will soon enter the pot party - Chicago Atlantic Real Estate Finance and Freehold Properties - both operating as mortgage REITs.

Cannabis REITs: When They Go Low, We Get High

PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ARNA--Arena achieved target enrollment in Study A of the CULTIVATE trial evaluating etrasimod in participants with moderate to severe Crohn's disease.

Arena Pharmaceuticals Achieves Target Enrollment for Etrasimod CULTIVATE Study A

Arena Pharmaceuticals (ARNA) misses Q3 bottom-line estimates. The company progresses with pipeline development.

Arena (ARNA) Q3 Loss Wider Than Anticipated, Revenues Nil

Arena Pharmaceuticals, Inc. (ARNA) CEO Amit Munshi on Q3 2021 Results - Earnings Call Transcript

Arena Pharmaceuticals, Inc. (ARNA) delivered earnings and revenue surprises of -32.64% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Arena Pharmaceuticals, Inc. (ARNA) Reports Q3 Loss, Lags Revenue Estimates

PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ARNA--Arena Pharmaceuticals, Inc. today provided a corporate update and reported financial results for the third quarter ended September 30, 2021.

Arena Reports Third Quarter Financial Results and Key Program Updates

PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ARNA--Arena Pharmaceuticals, Inc. will release its third quarter 2021 financial results and provide a corporate update on Thursday, November 4, 2021.

Arena Pharmaceuticals to Release Third Quarter 2021 Financial Results and Provide Corporate Update on November 4

After the recent FDA black box warning of JAKi, Arena Pharmaceuticals' share price has rallied recovering some of its 2021 losses. In this article, Etrasimod's ulcerative colitis phase 2 data will be analyzed and explain what our views for the S1P-R class moving forward.

Arena Pharmaceuticals: A Speculative Buy To Play The Upcoming Etrasimod's Data-Readout

Amarin Corporation Plc

Arcturus Therapeutics

bluebird bio

Cassava Sciences Inc

Theravance Biopharma

Buying biotech stocks while they're down is rewarding once they post positive clinical results, setting the stage for a big rally. The post 7 Busted Biotech Stocks Due for a Rebound appeared first on InvestorPlace.

7 Busted Biotech Stocks Due for a Rebound

PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ARNA--Arena to host two virtual R&D Investor calls for analysts and investors focused on etrasimod programs in gastroenterology and dermatology.

Arena Pharmaceuticals to Host Virtual R&D Investor Calls and Participate in Upcoming September Investor Conferences

Arena Pharmaceuticals, Inc. (ARNA) CEO Amit Munshi on Q2 2021 Results - Earnings Call Transcript

Arena Pharmaceuticals, Inc. (ARNA) delivered earnings and revenue surprises of -8.60% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Arena Pharmaceuticals, Inc. (ARNA) Reports Q2 Loss, Lags Revenue Estimates

PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ARNA--Arena Pharmaceuticals (Nasdaq: ARNA) today provided a corporate update and reported financial results for the second quarter ended June 30, 2021.

Arena Reports Second Quarter Financial Results and Key Program Updates

BRISBANE, Calif., Aug. 5, 2021 /PRNewswire/ -- Second Genome, a biotechnology company that leverages its proprietary platform sg-4-sight to discover and develop precision therapies and biomarkers from public and proprietary microbiome data, today announced they are entering a strategic collaboration with Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) to identify microbiome biomarkers associated with clinical response for their lead program in gastroenterology, etrasimod.

Second Genome Announces Collaboration with Arena Pharmaceuticals to Identify Gastrointestinal Biomarkers

PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ARNA--Arena will release second quarter 2021 financial results and provide a corporate update on August 5, after the close of the U.S. financial markets.

Arena Pharmaceuticals to Release Second Quarter 2021 Financial Results and Provide Corporate Update on August 5

PARK CITY, Utah, & SAN DIEGO--(BUSINESS WIRE)---- $ARNA #ARNA--Strategic collaboration and option agreement provides Arena with exclusive option to acquire Aristea and its CXCR2 programs post-Phase 2.

Arena Pharmaceuticals and Aristea Therapeutics Establish Collaboration for Development of RIST4721 for Treatment of Serious Immune-Mediated Inflammatory Diseases

News for Arena Pharmaceuticals Stock (ARNA)